Clinical Trial Update: Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial comparing dual antiplatelet therapy with rivaroxaban in atrial fibrillation patients undergoing left atrial appendage closure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Appendage
• Atrial Fibrillation

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Atrial Fibrillation, Atrial Appendage | Phase 2, Phase 3 | Status: COMPLETED